Colombel, Jean-FredericPanaccione, RemoBossuyt, PeterLukas, MilanBaert, FilipVanasek, TomasDanalioglu, AhmetNovacek, GottfriedArmuzzi, AlessandroHebuterne, XavierTravis, SimonDanese, SilvioReinisch, WalterSandborn, William J.Rutgeerts, PaulHommes, DanielSchreiber, StefanNeimark, EzequielHuang, BidanZhou, QianMendez, PalomaPetersson, JoelWallace, KoriRobinson, Anne M.Thakkar, Roopal B.D'Haens, Geert2020-10-222020-10-222017-12-01Colombel J., Panaccione R., Bossuyt P., Lukas M., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Hebuterne X., et al., -Effect of tight control management on Crohn-s disease (CALM): a multicentre, randomised, controlled phase 3 trial-, LANCET, cilt.390, ss.2779-2789, 2017http://hdl.handle.net/20.500.12645/23976https://www.sciencedirect.com/science/article/pii/S0140673617326417Background Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn-s disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn-s disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm.ArticleWOS:0004186698000238503366987810.1016/s0140-6736(17)32641-729096949